The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the tria

7 trials

Sponsors

Vicore Pharma (Sweden), Aardvark Therapeutics, Inc., Shionogi B.V., Novartis Pharmaceuticals UK Limited, BIAL Portela & Ca. S.A.

Conditions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. OtherThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Not SpecifiedThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Phase 1

Phase I Trial: Quotient Code QSC302899

Active, not recruitingISRCTN11464134

Shionogi B.V.The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2025-04-15Target: 7Updated: 2025-09-08

Phase 1 Trial: Quotient Code QSC303303, Sponsor Code LMNL6511C1002

RecruitingISRCTN96603462

Liminal BioSciences LimitedThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2025-06-02Target: 66Updated: 2025-09-08

Phase I Trial: Quotient Code QSC303217

RecruitingISRCTN11329248

Aardvark Therapeutics, Inc.The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2025-07-01Target: 20Updated: 2025-09-08

Phase I Study: Quotient Code QSC303166

RecruitingISRCTN47999700

Novartis Pharmaceuticals UK LimitedThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2025-09-05Target: 64Updated: 2025-09-15

Phase I Study: Quotient Code QSC300759

RecruitingISRCTN12269767

Novartis Pharmaceuticals UK LimitedThe sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2025-11-05Target: 16Updated: 2025-11-11

Phase I Study: Quotient Code QSC303294

RecruitingISRCTN16910437

BIAL Portela & Ca. S.A.The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Not Specified

Start: 2025-11-18Target: 26Updated: 2026-03-30

Phase I Trial: Quotient Code QSC303299

Active, not recruitingISRCTN10840798

Vicore Pharma (Sweden)The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Start: 2026-03-07Target: 8Updated: 2026-02-16